Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Université Paris-Sud · Inserm · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
890
total citations
- FWCI
- 37.23
- Percentile
- 100%
- References
- 87
Citations per year
Authors
23- SCStéphane Champiat
Université Paris-Sud, Inserm, Université Paris-Saclay, Institut Gustave Roussy
- OLOlivier Lambotte
Université Paris-Sud, Inserm, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, Assistance Publique – Hôpitaux de Paris, Infectious Disease Models and Innovative Therapies, Bicêtre Hospital
- EBEmmanuel Barreau
Bicêtre Hospital
- RBRakiba Belkhir
Assistance Publique – Hôpitaux de Paris, Bicêtre Hospital
- ABA. Berdelou
Université Paris-Sud, Université Paris-Saclay, Institut Gustave Roussy
Topics & keywords
Topics
Keywords
- Medicine
- Blockade
- Immune checkpoint
- Oncology
- Immunotherapy
- Nivolumab
- Adverse effect
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.